Insomnia - Pipeline Review, H2 2016

Date: November 9, 2016
Pages: 101
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: I3C9BDC2EBDEN
Leaflet:

Download PDF Leaflet

Insomnia - Pipeline Review, H2 2016
Insomnia - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Insomnia – Pipeline Review, H2 2016, provides an overview of the Insomnia (Central Nervous System) pipeline landscape.

Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches and distress in the stomach and intestines. Risk factors include age, mental health disorder, stress and shift working.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Insomnia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Insomnia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Insomnia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Insomnia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 9, 3, 6 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.Insomnia.

Insomnia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Insomnia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Insomnia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Insomnia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Insomnia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Insomnia (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Insomnia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Insomnia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Insomnia Overview
Therapeutics Development
Pipeline Products for Insomnia - Overview
Pipeline Products for Insomnia - Comparative Analysis
Insomnia - Therapeutics under Development by Companies
Insomnia - Therapeutics under Investigation by Universities/Institutes
Insomnia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Insomnia - Products under Development by Companies
Insomnia - Products under Investigation by Universities/Institutes
Insomnia - Companies Involved in Therapeutics Development
Actelion Ltd
Alexza Pharmaceuticals, Inc.
Eisai Co., Ltd.
Evotec AG
Grupo Ferrer Internacional, S.A.
Heptares Therapeutics Limited
Intec Pharma Ltd
Intra-Cellular Therapies, Inc.
Johnson & Johnson
Leading BioSciences, Inc.
Merck & Co., Inc.
Neurim Pharmaceuticals Ltd
Novartis AG
Reviva Pharmaceuticals Inc.
Shionogi & Co., Ltd.
Takeda Pharmaceutical Company Limited
Insomnia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(diphenhydramine + lorazepam + zolpidem tartrate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACT-541468 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-2810 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DORA-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Insomnia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit Angiotensin II Receptor Type 1 for Insomnia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EVT-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTL-6641 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ITI-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-42847922 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-48816274 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LASSBio-785 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LASSBio-786 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lemborexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lorediplon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-8133 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-1940 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piromelatine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ramelteon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-117957 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Insomnia, Obesity and Treatment Resistant Depression - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Orexin Receptor Type 1 and 2 for Insomnia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit OX2R for Insomnia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate CYP1A2 for Insomnia and Anxiety - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UCM-765 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zaleplon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zaleplon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zolpidem tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Insomnia - Dormant Projects
Insomnia - Discontinued Products
Insomnia - Product Development Milestones
Featured News & Press Releases
Sep 08, 2016: Ergomed Completes Recruitment of Phase IIa Clinical Trial of Lorediplon in Insomnia in Collaboration with co-development Partner Ferrer
Jul 07, 2016: Actelion To Enter Phase II Clinical Development With New Dual Orexin Receptor Antagonist In Patients With Insomnia
Jun 01, 2016: Minerva Neurosciences to Present data on MIN-202
Feb 01, 2016: Minerva Neurosciences Announces Top Line Data From MIN-202 Phase I Clinical Study in Japanese Patients
Jan 11, 2016: Minerva Neurosciences Announces Favorable Top Line Results From MIN-202 Phase 2A Clinical Trial in Insomnia Disorder
Dec 16, 2015: Intec Pharma Further Expands Intellectual Property with a New Patent for the Accordion Pill Zaleplon in Europe
Dec 09, 2015: Minerva Provides Year-End Update on Clinical Trial With Central Nervous System Product Candidate MIN-202
Sep 24, 2015: Minerva Neurosciences Provides Update on Clinical Development Program With MIN-202, Selective Orexin-2 Receptor Antagonist
Jul 14, 2015: Ferrer initiates phase IIa clinical study of Lorediplon in patients with insomnia
Jun 16, 2015: Minerva Neurosciences Provides Update on MIN-202, Selective Orexin-2 Receptor Antagonist
Jan 21, 2015: Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia
Dec 10, 2014: Eisai Demonstrates Efficacy Of Investigational Dual Orexin Receptor Antagonist E2006 In Sleep Initiation And Maintenance
Sep 22, 2014: Minerva Neurosciences Announces Completion of FDA Review of Investigational New Drug Application for MIN-202 and Plans for First U.S.-Based Clinical Trial
Jul 26, 2013: Takeda Pharma Receives FDA Approval For Rozerem
Feb 18, 2013: Neurim Pharma Announces Positive Phase II Clinical Trial Results Of Piromelatine For Treatment Of Insomnia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Insomnia, H2 2016
Number of Products under Development for Insomnia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Insomnia - Pipeline by Actelion Ltd, H2 2016
Insomnia - Pipeline by Alexza Pharmaceuticals, Inc., H2 2016
Insomnia - Pipeline by Eisai Co., Ltd., H2 2016
Insomnia - Pipeline by Evotec AG, H2 2016
Insomnia - Pipeline by Grupo Ferrer Internacional, S.A., H2 2016
Insomnia - Pipeline by Heptares Therapeutics Limited, H2 2016
Insomnia - Pipeline by Intec Pharma Ltd, H2 2016
Insomnia - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
Insomnia - Pipeline by Johnson & Johnson, H2 2016
Insomnia - Pipeline by Leading BioSciences, Inc., H2 2016
Insomnia - Pipeline by Merck & Co., Inc., H2 2016
Insomnia - Pipeline by Neurim Pharmaceuticals Ltd, H2 2016
Insomnia - Pipeline by Novartis AG, H2 2016
Insomnia - Pipeline by Reviva Pharmaceuticals Inc., H2 2016
Insomnia - Pipeline by Shionogi & Co., Ltd., H2 2016
Insomnia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Insomnia - Dormant Projects, H2 2016
Insomnia - Dormant Projects (Contd..1), H2 2016
Insomnia - Dormant Projects (Contd..2), H2 2016
Insomnia - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Insomnia, H2 2016
Number of Products under Development for Insomnia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Insomnia - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: